Dimitrios A Pappas

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 21

Top Topics

Machine Learning

Disease Activity

Interstitial Lung Disease

Top Venues

Arthritis research & therapy

Annals of the rheumatic diseases

Rheumatology international

ACR open rheumatology

This page only lists publications with an associated author ORCID identifier.

Publications

Anthony Sebba, Clifton O Bingham, Vivian P Bykerk, Stefano Fiore, Kerri Ford, Jud C Janak, Dimitrios A Pappas, Taylor Blachley, Swapna S Dave, Joel M Kremer, Miao Yu, Ernest H S Choy
Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry. Clinical rheumatology (2023)
Anisha B Dua, Kerri Ford, Stefano Fiore, Dimitrios A Pappas, Jud C Janak, Taylor Blachley, Carla Roberts-Toler, Kelechi Emeanuru, Joel M Kremer, Alan J Kivitz
Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study. Rheumatology and therapy (2023)
Dimitrios A Pappas, Jacqueline O'Brien, Lin Guo, Ying Shan, Joshua F Baker, Gregory Kricorian, Scott Stryker, David H Collier
Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry. Arthritis research & therapy 25 (1) (2023)
Anthony S Padula, Dimitrios A Pappas, Stefano Fiore, Taylor S Blachley, Kerri Ford, Kelechi Emeanuru, Joel M Kremer
The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry. Arthritis research & therapy 24 (1) (2022)
Anthony S Padula, Dimitrios A Pappas, Stefano Fiore, Taylor S Blachley, Kerri Ford, Kelechi Emeanuru, Joel M Kremer
The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry. Arthritis research & therapy 24 (1) (2022)
Anthony S Padula, Dimitrios A Pappas, Stefano Fiore, Taylor S Blachley, Kerri Ford, Kelechi Emeanuru, Joel M Kremer
The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry. Arthritis research & therapy 24 (1) (2022)
Dimitrios A Pappas, Christine Brittle, Andrew Concoff, Andrew J Holman, Dennis Takasugi, Joel M Kremer
Perspectives on applying immuno-autonomics to rheumatoid arthritis: results from an online rheumatologist survey. Rheumatology international 42 (9) (2022)
Anthony S Padula, Dimitrios A Pappas, Stefano Fiore, Taylor S Blachley, Kerri Ford, Kelechi Emeanuru, Joel M Kremer
The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry. Arthritis research & therapy 24 (1) (2022)
Anthony S Padula, Dimitrios A Pappas, Stefano Fiore, Taylor S Blachley, Kerri Ford, Kelechi Emeanuru, Joel M Kremer
The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry. Arthritis research & therapy 24 (1) (2022)
Anthony James Ocon, George Reed, Dimitrios A Pappas, Jeffrey R Curtis, Joel M Kremer
Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. Annals of the rheumatic diseases 80 (12) (2021)
Joel M Kremer, George Reed, Dimitrios A Pappas, Kevin Kane, Vivi L Feathers, Michael E Weinblatt, Nancy A Shadick, Jeffrey D Greenberg, Leslie R Harrold
Dr. Kremer et al reply. The Journal of rheumatology (2021)
Jeffrey R Curtis, J Lynn Palmer, George W Reed, Jeffrey Greenberg, Dimitrios A Pappas, Leslie R Harrold, Joel M Kremer
Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. Arthritis care & research 73 (8) (2021)
Joel M Kremer, Clifton O Bingham, Laura C Cappelli, Jeffrey D Greenberg, Ann M Madsen, Jamie Geier, Jose L Rivas, Alina M Onofrei, Christine J Barr, Dimitrios A Pappas, Heather J Litman, Kimberly J Dandreo, Andrea B Shapiro, Carol A Connell, Arthur Kavanaugh
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry. ACR open rheumatology 3 (3) (2021)
Jeffrey R Curtis, Joel M Kremer, George Reed, Ani K John, Dimitrios A Pappas
TNFi Cycling Versus Changing Mechanism of Action in TNFi-Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study. ACR open rheumatology (2021)
Dimitrios A Pappas, Gregory St John, Carol J Etzel, Stefano Fiore, Taylor Blachley, Toshio Kimura, Rajeshwari Punekar, Kelechi Emeanuru, Jeannie Choi, Susan Boklage, Joel M Kremer
Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'' by Zheng et al. Annals of the rheumatic diseases (2020)
Dimitrios A Pappas, Ying Shan, Tamara Lesperance, Greg Kricorian, Elaine Karis, Sabrina Rebello, Winnie Hua, Neil A Accortt, Scott Stryker
Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry. ACR open rheumatology 2 (10) (2020)
Dimitrios A Pappas, Christine Brittle, James E Mossell, Johanna B Withers, Jeraldine Lim-Harashima, Joel M Kremer
Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study. Rheumatology international 41 (3) (2020)
Dimitrios A Pappas, Gregory St John, Carol J Etzel, Stefano Fiore, Taylor Blachley, Toshio Kimura, Rajeshwari Punekar, Kelechi Emeanuru, Jeannie Choi, Susan Boklage, Joel M Kremer
Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Annals of the rheumatic diseases 80 (1) (2020)
Dimitrios A Pappas, Heather J Litman, Tamara Lesperance, Greg Kricorian, Elaine Karis, Sabrina Rebello, Winnie Hua, Neil A Accortt, Scott Stryker
Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data. Rheumatology international 41 (2) (2020)
Kevin L Winthrop, Gustavo Citera, David Gold, Dan Henrohn, Carol A Connell, Andrea B Shapiro, Harry Shi, Alina M Onofrei, Dimitrios A Pappas, Hendrik Schulze-Koops
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry. Annals of the rheumatic diseases 80 (1) (2020)
Yuanfang Guan, Hongjiu Zhang, Daniel Quang, Ziyan Wang, Stephen C J Parker, Dimitrios A Pappas, Joel M Kremer, Fan Zhu
Machine Learning to Predict Anti-Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers. Arthritis & rheumatology (Hoboken, N.J.) 71 (12) (2019)